(Total Views: 619)
Posted On: 06/29/2020 10:27:21 AM
Post# of 9148
interesting insight into how big pharma prices its products in new article:
"In normal circumstances, we would price a medicine according to the value it provides. The first results from the NIAID study in hospitalized patients with COVID-19 showed that remdesivir shortened time to recovery by an average of four days," O'Day wrote in the letter, explaining the pricing decisions. "Taking the example of the United States, earlier hospital discharge would result in hospital savings of approximately $12,000 per patient. Even just considering these immediate savings to the healthcare system alone, we can see the potential value that remdesivir provides. This is before we factor in the direct benefit to those patients who may have a shorter stay in the hospital."
https://www.foxnews.com/science/gilead-sets-c...ivir-price
"In normal circumstances, we would price a medicine according to the value it provides. The first results from the NIAID study in hospitalized patients with COVID-19 showed that remdesivir shortened time to recovery by an average of four days," O'Day wrote in the letter, explaining the pricing decisions. "Taking the example of the United States, earlier hospital discharge would result in hospital savings of approximately $12,000 per patient. Even just considering these immediate savings to the healthcare system alone, we can see the potential value that remdesivir provides. This is before we factor in the direct benefit to those patients who may have a shorter stay in the hospital."
https://www.foxnews.com/science/gilead-sets-c...ivir-price
(0)
(0)
